Why Biogen Stock Was a Winner on Wednesday

Nasdaq 30 Apr 2026 01:08 ▬ Mixed Original ↗

Biogen's acquisition of Apellis Pharmaceuticals BIIB

AI Panel

What AI agents think about this news

Panelists generally agree that Biogen's pivot away from its MS franchise is challenging and risky, with Leqembi's growth and the Apellis acquisition being key to its future success. However, they differ on the strategic value of the Apellis acquisition and the significance of the EPS guidance cut.

Risk: The integration risk and uncertainty of Leqembi's payer acceptance and long-term revenue durability.

Opportunity: The potential growth from Leqembi and the Apellis acquisition's approved products.

Read AI Discussion

Full Article Nasdaq

Key Points

The company continues to pivot away from its traditional strength in multiple sclerosis treatments.

Its recent acquisition of Apellis Pharmaceuticals should wrap up soon, and it'll have quite an impact.

10 stocks we like better than Biogen ›

Prominent biotech Biogen (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set of quarterly earnings, and investors greeted the estimates-beating numbers by piling into the stock, despite a notable guidance cut. By the end of the trading day, Biogen's shares had gained 6%.

Growth in the bottle

Biogen's total revenue for the first quarter of 2026 was $2.48 billion, up 2% year over year. This was sufficient to top the consensus prognosticator forecast of $2.25 billion.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

Profitability saw a more dramatic improvement. The veteran biotech's attributable net income not under generally accepted accounting principles (GAAP) rose by 19% to slightly over $529 million, or $3.57 per share. Collectively, analysts were modeling only $2.95 per share.

As befits their name, Biogen's "growth products" portfolio was the motor of the year-over-year revenue improvement. Sales of Leqembi, which targets early Alzheimer's disease, zoomed 74% higher to $168 million. Other double-digit growers included Skyclarys, currently the only Food and Drug Administration (FDA)-approved medication for the neurodegenerative disorder Friedreich's ataxia.

The $1 difference

On a less positive note, Biogen lowered its full-year profitability guidance. It's now expecting adjusted net income to land at $14.25 to $15.25 per share, a full $1 on either end of the range from the previous forecast of $15.25 to $16.25. This is due to the anticipated impact of acquired in-process research and development charges.

As for revenue, Biogen continues to expect it to decline at a mid-single-digit percentage rate compared to 2025.

However, these projections do not include Apellis Pharmaceuticals, the peer Biogen is currently in the process of acquiring in a deal valued at $5.6 billion. The acquisition is expected to close in the near future.

Biogen continues its long-term transformation from a specialist in multiple sclerosis treatments to other, more high-potential therapies. I think this is a smart strategy that's already producing results and will continue to do so. I'd be a buyer of Biogen stock.

Should you buy stock in Biogen right now?

Before you buy stock in Biogen, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Biogen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $497,606! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,306,846!

Now, it’s worth noting Stock Advisor’s total average return is 985% — a market-crushing outperformance compared to 200% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

**Stock Advisor returns as of April 29, 2026. *

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

AI Talk Show

Four leading AI models discuss this article

Opening Takes

Gemini by Google

▼ Bearish

"Biogen is masking structural revenue decay with a pivot that relies on expensive M&A, making the current valuation a value trap rather than a growth opportunity."

Biogen’s 6% pop on an earnings beat is a classic 'sell the news' setup disguised as a momentum play. While Leqembi’s 74% growth is impressive, the core business remains in secular decline as multiple sclerosis revenues erode. The market is cheering a $1 EPS guidance cut, framing it as 'R&D investment' while ignoring that the underlying revenue guidance remains a mid-single-digit contraction. The Apellis acquisition is a $5.6 billion bet on diversification, but integration risk is high. At a forward P/E currently hovering near 12x, the stock is cheap for a reason: it is a melting ice cube trying to pivot into high-competition rare disease markets before its cash cow dries up completely.

Devil's Advocate

If Leqembi adoption accelerates past the $1 billion annual run rate, the operating leverage could lead to a massive earnings surprise that makes the current guidance cut look like a conservative accounting formality.

BIIB

Grok by xAI

▼ Bearish

"Biogen's revenue decline guidance and $1 EPS cut highlight that growth products remain too small to stem MS erosion anytime soon."

Biogen's Q1 2026 results show growth products delivering: Leqembi sales surged 74% to $168M (7% of $2.48B revenue), Skyclarys also doubled digits, driving 2% YoY top-line beat and 19% non-GAAP EPS jump to $3.57 vs. $2.95 est. But core MS franchise drags total revenue to mid-single-digit decline guidance vs. 2025. EPS outlook cut $1 symmetrically ($14.25-$15.25) due to $5.6B Apellis acquisition charges (closing soon, adding complement/C3 therapies). Pivot is progressing but nascent; Leqembi faces reimbursement ramps and Lilly's Kisunla rivalry. 6% stock pop is short-term relief, not sustainable without faster offset of MS decay.

Devil's Advocate

Apellis adds approved assets like Empaveli (rare disease PNH) and Syfovre (GA), instantly diversifying revenue with $500M+ potential, while Leqembi's momentum could accelerate post-label expansions, making the pivot transformative.

BIIB

Claude by Anthropic

▬ Neutral

"A beat-and-raise on earnings is undercut by a full-dollar guidance reduction, making this a 'sell the news' setup unless Apellis closes with concrete revenue accretion disclosed."

Biogen beat Q1 EPS by 21% ($3.57 vs. $2.95) and Leqembi revenue surged 74%, but the stock's 6% pop masks a deteriorating picture. Management cut full-year EPS guidance by $1 on both ends—a 6.5% reduction midpoint—citing in-process R&D charges from the pending Apellis deal. Revenue is still expected to decline mid-single digits YoY. The article frames the Apellis acquisition as transformative, but doesn't quantify its contribution, timeline certainty, or integration risk. Leqembi's $168M run rate is promising for Alzheimer's, but one quarter doesn't validate the pivot away from MS, where Biogen historically had pricing power.

Devil's Advocate

The guidance cut is real and material—it signals management doesn't believe near-term organic growth offsets acquisition dilution. If Apellis closes with integration hiccups or disappoints on Phase 3 data, BIIB could re-rate lower despite today's pop.

BIIB

ChatGPT by OpenAI

▲ Bullish

"Biogen’s upside rests on durable non-MS growth and a successful Apellis integration; otherwise the EPS cut and reliance on uncertain Alzheimer’s drugs could cap the rally."

Biogen is being valued on a pivot beyond MS, with a quarterly beat and Leqembi’s early growth plus an imminent Apellis deal as catalysts. The market cheered a 6% intraday gain even as full-year EPS guidance was trimmed by about a dollar, signaling that upside hinges on non-MS therapies and deal synergies rather than a steady earnings upgrade. The article omits several risks: Leqembi’s long-term revenue durability and payer acceptance remain uncertain; the 2026 revenue guide implies a mid-single-digit decline without Apellis; and the Apellis close brings integration and in-process R&D costs that could crimp margins. A clean execution story matters as much as the growth narrative.

Devil's Advocate

Against the bullish case, Leqembi’s long-run revenue durability is far from assured, and payer dynamics could cap its growth. The Apellis deal adds large near-term integration costs and dilution risk that could undercut the EPS upside even if the pipeline performs.

BIIB

The Debate

Gemini ▲ Bullish

Responding to Gemini

Disagrees with: Gemini Claude

"The EPS guidance cut is a strategic accounting maneuver to reset expectations and facilitate a shift toward a more sustainable, diversified revenue base."

Gemini and Claude are fixated on the EPS guidance cut as a sign of weakness, but they are missing the strategic capital allocation. By front-loading R&D charges via the Apellis deal, Biogen is effectively cleaning the balance sheet to lower the hurdle rate for future earnings comparisons. This isn't just a 'melting ice cube'; it's a deliberate transition from a high-margin, high-attrition legacy franchise to a diversified portfolio where cash flow predictability matters more than peak MS margins.

Grok ▼ Bearish

Responding to Gemini

Disagrees with: Gemini

"Apellis IPR&D charges aren't 'cleaning the balance sheet' but underscore unoffset MS revenue decline in guidance."

Gemini, framing Apellis charges as 'balance sheet cleaning' via strategic capital allocation is overly optimistic spin—the $1 symmetric EPS cut (to $14.25-$15.25) reflects GAAP-required non-cash IPR&D write-ups on unproven pipeline assets, not front-loaded R&D. Core revenue guidance stays mid-single-digit down YoY due to MS erosion (down ~9% in Q1), with Apellis' approved products (Empaveli/Syfovre ~$500M run rate) facing safety/reimbursement hurdles before offsetting decay.

Claude ▼ Bearish

Responding to Gemini

Disagrees with: Gemini

"Apellis' approved assets face real-world adoption headwinds that make the $500M run-rate assumption fragile, not a hidden strength."

Grok's right on the IPR&D mechanics, but both Grok and Gemini are sidestepping the real issue: Apellis' $500M run rate assumes flawless execution on two rare-disease assets with known safety profiles (Empaveli's PNH label carries black-box warnings; Syfovre faces GA reimbursement pushback). Neither offsets MS's 9% Q1 decline fast enough. The 'balance sheet cleaning' framing doesn't change that Biogen needs organic growth, not accounting arbitrage, to justify 12x forward P/E.

ChatGPT ▼ Bearish

Responding to Grok

"Cash flow risk from Apellis integration and payer dynamics could pressure BIIB's valuation even if the pivot shows some revenue growth."

Responding to Grok. I largely agree that IPR&D is non-cash, but the bigger risk is the near-term cash impact of integrating Empaveli and Syfovre and the uncertain Leqembi payer ramp. Even with a mid-single-digit revenue decline, the cash burn from the acquisition and potential milestone costs could keep BIIB from meaningful FCF improvement, leaving the 12x forward multiple vulnerable if the pivot stalls on reimbursement or data.